Department of Emergency Medicine University of Ottawa Ottawa Ontario Canada.
Division of Neurology McMaster University Hamilton Ontario Canada.
J Am Heart Assoc. 2023 Apr 18;12(8):e026681. doi: 10.1161/JAHA.122.026681. Epub 2023 Apr 7.
Background For patients with atrial fibrillation seen in the emergency department (ED) following a transient ischemic attack (TIA) or minor stroke, the impact of initiating oral anticoagulation immediately rather than deferring the decision to outpatient follow-up is unknown. Methods and Results We conducted a planned secondary data analysis of a prospective cohort of 11 507 adults in 13 Canadian EDs between 2006 and 2018. Patients were eligible if they were aged 18 years or older, with a final diagnosis of TIA or minor stroke with previously documented or newly diagnosed atrial fibrillation. The primary outcome was subsequent stroke, recurrent TIA, or all-cause mortality within 90 days of the index TIA diagnosis. Secondary outcomes included stroke, recurrent TIA, or death and rates of major bleeding. Of 11 507 subjects with TIA/minor stroke, atrial fibrillation was identified in 11.2% (1286, mean age, 77.3 [SD 11.1] years, 52.4% male). Over half (699; 54.4%) were already taking anticoagulation, 89 (6.9%) were newly prescribed anticoagulation in the ED. By 90 days, 4.0% of the atrial fibrillation cohort had experienced a subsequent stroke, 6.5% subsequent TIA, and 2.6% died. Results of a multivariable logistic regression indicate no association between prescribed anticoagulation in the ED and these 90-day outcomes (composite odds ratio, 1.37 [95% CI, 0.74-2.52]). Major bleeding was found in 5 patients, none of whom were in the ED-initiated anticoagulation group. Conclusions Initiating oral anticoagulation in the ED following new TIA was not associated with lower recurrence rates of neurovascular events or all-cause mortality in patients with atrial fibrillation.
对于在急诊科(ED)就诊的因短暂性脑缺血发作(TIA)或小卒中而发生心房颤动的患者,立即开始口服抗凝治疗而不是推迟门诊随访的决策对其影响尚不清楚。
我们对 2006 年至 2018 年期间在加拿大 13 个急诊科的 11507 名成年人进行了一项前瞻性队列的计划二次数据分析。如果患者年龄在 18 岁或以上,有 TIA 或小卒中的最终诊断,且有先前记录或新诊断的心房颤动,则符合入选条件。主要结局是 TIA 诊断后 90 天内的后续卒中、复发性 TIA 或全因死亡率。次要结局包括卒中、复发性 TIA 或死亡以及大出血发生率。在 11507 例 TIA/小卒中患者中,有 11.2%(1286 例,平均年龄 77.3[11.1]岁,52.4%为男性)发现心房颤动。超过一半(699 例;54.4%)正在服用抗凝药物,89 例(6.9%)在急诊科新开抗凝药物。在 90 天内,心房颤动组有 4.0%的患者发生了后续卒中,6.5%的患者发生了后续 TIA,2.6%的患者死亡。多变量逻辑回归的结果表明,ED 中开具的抗凝药物与这些 90 天结局之间没有关联(复合优势比,1.37[95%CI,0.74-2.52])。发现 5 例大出血,均未发生在 ED 开始抗凝治疗组。
在新发 TIA 后,在 ED 开始口服抗凝治疗与心房颤动患者神经血管事件或全因死亡率的降低无关。